Author

M. Wiech

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Organism:multiple species· 1

Frequent Co-Authors

A. Cariani· 1 shared A. J. Andrews· 1 shared A. Klejman· 1 shared A. Kominek· 1 shared B. Star· 1 shared E. Cilli· 1 shared E. F. Eriksen· 1 shared E. Malca· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperEvolutionary Biology

A. Cariani

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Five millennia of mitochondrial introgression in Atlantic bluefin tuna identified using ancient DNA

E. F. Eriksen, A. J. Andrews, S. V. Nielsen, P. Persson, E. Malca, V. Onar, V. Aniceti, G. Piques, F. Piattoni, F. Fontani, M. Wiech, K. Ferter, O. Kersten, G. Ferrari, A. Cariani, , B. Star

This study uses ancient DNA to show that mitochondrial introgression in Atlantic bluefin tuna has persisted for five millennia without significant anthropogenic impact.

bioRxiv · Mar 24, 2024 · PreprintEvolutionary Biology

Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cells

W. Dudka, G. Hoser, S. S. Mondal, L. Turos-Korgul, J. Swatler, M. Kusio-Kobiałka, M. Wolczyk, A. Klejman, M. Brewinska-Olchowik, A. Kominek, M. Wiech, M. M. Machnicki, I. Seferynska, T. Stoklosa, K. Piwocka

This study shows that combining ISRIB with imatinib reduces STAT5 signaling and eliminates imatinib-resistant CML cells by altering transcriptomic profiles.

bioRxiv · May 5, 2021 · PreprintCancer Biology